ID   ADCY8_RAT               Reviewed;        1248 AA.
AC   P40146;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1995, sequence version 1.
DT   29-MAY-2024, entry version 163.
DE   RecName: Full=Adenylate cyclase type 8 {ECO:0000305};
DE            EC=4.6.1.1 {ECO:0000269|PubMed:8163524, ECO:0000269|PubMed:8557635};
DE   AltName: Full=ATP pyrophosphate-lyase 8;
DE   AltName: Full=Adenylate cyclase type VIII {ECO:0000250|UniProtKB:P40145};
DE   AltName: Full=Adenylyl cyclase 8 {ECO:0000303|PubMed:16741924};
DE   AltName: Full=Ca(2+)/calmodulin-activated adenylyl cyclase;
GN   Name=Adcy8 {ECO:0000312|RGD:2036};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   SUBCELLULAR LOCATION, AND ACTIVITY REGULATION.
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RX   PubMed=8163524; DOI=10.1016/s0021-9258(17)32700-x;
RA   Cali J.J., Zwaagstra J.C., Mons N., Cooper D.M., Krupinski J.;
RT   "Type VIII adenylyl cyclase. A Ca2+/calmodulin-stimulated enzyme expressed
RT   in discrete regions of rat brain.";
RL   J. Biol. Chem. 269:12190-12195(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), TISSUE SPECIFICITY,
RP   GLYCOSYLATION (ISOFORMS 1 AND 3), ACTIVITY REGULATION, CATALYTIC ACTIVITY,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND COFACTOR.
RX   PubMed=8557635; DOI=10.1074/jbc.271.2.1089;
RA   Cali J.J., Parekh R.S., Krupinski J.;
RT   "Splice variants of type VIII adenylyl cyclase. Differences in
RT   glycosylation and regulation by Ca2+/calmodulin.";
RL   J. Biol. Chem. 271:1089-1095(1996).
RN   [3]
RP   SUBUNIT, AND DOMAIN.
RX   PubMed=11856299; DOI=10.1046/j.0014-2956.2001.02708.x;
RA   Gu C., Cali J.J., Cooper D.M.;
RT   "Dimerization of mammalian adenylate cyclases.";
RL   Eur. J. Biochem. 269:413-421(2002).
RN   [4]
RP   MUTAGENESIS OF 38-TRP--THR-40 AND 49-ARG--ILE-51, ACTIVITY REGULATION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=11744699; DOI=10.1074/jbc.m109615200;
RA   Smith K.E., Gu C., Fagan K.A., Hu B., Cooper D.M.;
RT   "Residence of adenylyl cyclase type 8 in caveolae is necessary but not
RT   sufficient for regulation by capacitative Ca(2+) entry.";
RL   J. Biol. Chem. 277:6025-6031(2002).
RN   [5]
RP   ACTIVITY REGULATION, FUNCTION, TISSUE SPECIFICITY, AND ALTERNATIVE SPLICING
RP   (ISOFORM 4).
RX   PubMed=13680124; DOI=10.1007/s00125-003-1203-8;
RA   Delmeire D., Flamez D., Hinke S.A., Cali J.J., Pipeleers D., Schuit F.;
RT   "Type VIII adenylyl cyclase in rat beta cells: coincidence signal
RT   detector/generator for glucose and GLP-1.";
RL   Diabetologia 46:1383-1393(2003).
RN   [6]
RP   ACTIVITY REGULATION.
RX   PubMed=16186630; DOI=10.1385/jmn:27:2:195;
RA   Steiner D., Avidor-Reiss T., Schallmach E., Saya D., Vogel Z.;
RT   "Inhibition and superactivation of the calcium-stimulated isoforms of
RT   adenylyl cyclase: role of Gbetagamma dimers.";
RL   J. Mol. Neurosci. 27:195-203(2005).
RN   [7]
RP   INDUCTION, AND FUNCTION.
RX   PubMed=16741924; DOI=10.1002/jcp.20673;
RA   Clement N., Glorian M., Raymondjean M., Andreani M., Limon I.;
RT   "PGE2 amplifies the effects of IL-1beta on vascular smooth muscle cell de-
RT   differentiation: a consequence of the versatility of PGE2 receptors 3 due
RT   to the emerging expression of adenylyl cyclase 8.";
RL   J. Cell. Physiol. 208:495-505(2006).
RN   [8]
RP   INTERACTION WITH PPP2CA; CALM1 AND PPP2R1A, REGION, MUTAGENESIS OF
RP   38-TRP--THR-40 AND 49-ARG--ILE-51, SUBCELLULAR LOCATION, AND MOTIF.
RX   PubMed=16258073; DOI=10.1124/mol.105.018275;
RA   Crossthwaite A.J., Ciruela A., Rayner T.F., Cooper D.M.;
RT   "A direct interaction between the N terminus of adenylyl cyclase AC8 and
RT   the catalytic subunit of protein phosphatase 2A.";
RL   Mol. Pharmacol. 69:608-617(2006).
RN   [9]
RP   SUBUNIT, GLYCOSYLATION, MUTAGENESIS OF LEU-432; LEU-439; LEU-446; LEU-453;
RP   ASN-814; ASN-818 AND ASN-885, ACTIVITY REGULATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=19158400; DOI=10.1152/ajpcell.00488.2008;
RA   Pagano M., Clynes M.A., Masada N., Ciruela A., Ayling L.J., Wachten S.,
RA   Cooper D.M.;
RT   "Insights into the residence in lipid rafts of adenylyl cyclase AC8 and its
RT   regulation by capacitative calcium entry.";
RL   Am. J. Physiol. 296:C607-C619(2009).
RN   [10]
RP   REGION, MUTAGENESIS OF 38-TRP--THR-40; 49-ARG--ILE-51; LEU-1196; VAL-1197;
RP   GLN-1198; SER-1199; LEU-1200; ARG-1202; ARG-1204; LYS-1206; LEU-1208 AND
RP   LEU-1209, ACTIVITY REGULATION, SITE, DOMAIN, AND INTERACTION WITH
RP   CALMODULIN.
RX   PubMed=19305019; DOI=10.1074/jbc.m809585200;
RA   Macdougall D.A., Wachten S., Ciruela A., Sinz A., Cooper D.M.;
RT   "Separate elements within a single IQ-like motif in adenylyl cyclase type 8
RT   impart ca2+/calmodulin binding and autoinhibition.";
RL   J. Biol. Chem. 284:15573-15588(2009).
RN   [11]
RP   SUBCELLULAR LOCATION, AND ACTIVITY REGULATION.
RX   PubMed=19171672; DOI=10.1124/mol.108.051748;
RA   Martin A.C., Willoughby D., Ciruela A., Ayling L.J., Pagano M., Wachten S.,
RA   Tengholm A., Cooper D.M.;
RT   "Capacitative Ca2+ entry via Orai1 and stromal interacting molecule 1
RT   (STIM1) regulates adenylyl cyclase type 8.";
RL   Mol. Pharmacol. 75:830-842(2009).
RN   [12]
RP   INTERACTION WITH AKAP5, AND ACTIVITY REGULATION.
RX   PubMed=20410303; DOI=10.1074/jbc.m110.120725;
RA   Willoughby D., Masada N., Wachten S., Pagano M., Halls M.L., Everett K.L.,
RA   Ciruela A., Cooper D.M.;
RT   "AKAP79/150 interacts with AC8 and regulates Ca2+-dependent cAMP synthesis
RT   in pancreatic and neuronal systems.";
RL   J. Biol. Chem. 285:20328-20342(2010).
RN   [13]
RP   INDUCTION, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=21046358; DOI=10.1007/s00125-010-1955-x;
RA   Roger B., Papin J., Vacher P., Raoux M., Mulot A., Dubois M.,
RA   Kerr-Conte J., Voy B.H., Pattou F., Charpentier G., Jonas J.C.,
RA   Moustaid-Moussa N., Lang J.;
RT   "Adenylyl cyclase 8 is central to glucagon-like peptide 1 signalling and
RT   effects of chronically elevated glucose in rat and human pancreatic beta
RT   cells.";
RL   Diabetologia 54:390-402(2011).
RN   [14]
RP   INTERACTION WITH AKAP5, PHOSPHORYLATION, AND ACTIVITY REGULATION.
RX   PubMed=21771783; DOI=10.1074/jbc.m111.243899;
RA   Delint-Ramirez I., Willoughby D., Hammond G.V., Ayling L.J., Cooper D.M.;
RT   "Palmitoylation targets AKAP79 protein to lipid rafts and promotes its
RT   regulation of calcium-sensitive adenylyl cyclase type 8.";
RL   J. Biol. Chem. 286:32962-32975(2011).
RN   [15]
RP   MUTAGENESIS OF 1-MET--PHE-106 AND ASP-416, AND INTERACTION WITH ACTIN AND
RP   CALM1.
RX   PubMed=22399809; DOI=10.1242/jcs.091090;
RA   Ayling L.J., Briddon S.J., Halls M.L., Hammond G.R., Vaca L., Pacheco J.,
RA   Hill S.J., Cooper D.M.;
RT   "Adenylyl cyclase AC8 directly controls its micro-environment by recruiting
RT   the actin cytoskeleton in a cholesterol-rich milieu.";
RL   J. Cell Sci. 125:869-886(2012).
RN   [16]
RP   ACTIVITY REGULATION, INTERACTION WITH PRKAR2A; PPP2CA; PPP2R5D AND AKAP5,
RP   REGION, MUTAGENESIS OF SER-66; SER-112; SER-178; SER-611; SER-852 AND
RP   SER-1120, AND PHOSPHORYLATION.
RX   PubMed=22976297; DOI=10.1242/jcs.111427;
RA   Willoughby D., Halls M.L., Everett K.L., Ciruela A., Skroblin P.,
RA   Klussmann E., Cooper D.M.;
RT   "A key phosphorylation site in AC8 mediates regulation of Ca(2+)-dependent
RT   cAMP dynamics by an AC8-AKAP79-PKA signalling complex.";
RL   J. Cell Sci. 125:5850-5859(2012).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-621, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [18]
RP   INTERACTION WITH ORAI1 AND STIM1, REGION, SUBCELLULAR LOCATION, FUNCTION,
RP   AND ACTIVITY REGULATION.
RX   PubMed=22494970; DOI=10.1126/scisignal.2002299;
RA   Willoughby D., Everett K.L., Halls M.L., Pacheco J., Skroblin P., Vaca L.,
RA   Klussmann E., Cooper D.M.;
RT   "Direct binding between Orai1 and AC8 mediates dynamic interplay between
RT   Ca2+ and cAMP signaling.";
RL   Sci. Signal. 5:RA29-RA29(2012).
RN   [19]
RP   ACTIVITY REGULATION, AND FUNCTION.
RX   PubMed=24086669; DOI=10.1371/journal.pone.0075942;
RA   Everett K.L., Cooper D.M.;
RT   "An improved targeted cAMP sensor to study the regulation of adenylyl
RT   cyclase 8 by Ca2+ entry through voltage-gated channels.";
RL   PLoS ONE 8:E75942-E75942(2013).
RN   [20]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=25381556; DOI=10.1007/s00125-014-3437-z;
RA   Dou H., Wang C., Wu X., Yao L., Zhang X., Teng S., Xu H., Liu B., Wu Q.,
RA   Zhang Q., Hu M., Wang Y., Wang L., Wu Y., Shang S., Kang X., Zheng L.,
RA   Zhang J., Raoux M., Lang J., Li Q., Su J., Yu X., Chen L., Zhou Z.;
RT   "Calcium influx activates adenylyl cyclase 8 for sustained insulin
RT   secretion in rat pancreatic beta cells.";
RL   Diabetologia 58:324-333(2015).
CC   -!- FUNCTION: Catalyzes the formation of cAMP in response to calcium entry
CC       leadings to cAMP signaling activation that affect processes suche as
CC       synaptic plasticity and insulin secretion (PubMed:13680124,
CC       PubMed:21046358, PubMed:22494970, PubMed:24086669, PubMed:25381556,
CC       PubMed:8163524). Plays a role in many brain functions, such as
CC       learning, memory, drug addiction, and anxiety modulation through
CC       regulation of synaptic plasticity by modulating long-term memory and
CC       long-term potentiation (LTP) through CREB transcription factor activity
CC       modulation (PubMed:8163524). Plays a central role in insulin secretion
CC       by controlling glucose homeostasis through glucagon-like peptide 1 and
CC       glucose signaling pathway and maintains insulin secretion through
CC       calcium-dependent PKA activation leading to vesicle pool replenishment
CC       (PubMed:13680124, PubMed:21046358, PubMed:25381556). Also, allows
CC       PTGER3 to induce potentiation of PTGER4-mediated PLA2 secretion by
CC       switching from a negative to a positive regulation, during the IL1B
CC       induced-dedifferentiation of smooth muscle cells (PubMed:16741924).
CC       {ECO:0000269|PubMed:13680124, ECO:0000269|PubMed:16741924,
CC       ECO:0000269|PubMed:21046358, ECO:0000269|PubMed:22494970,
CC       ECO:0000269|PubMed:24086669, ECO:0000269|PubMed:25381556,
CC       ECO:0000269|PubMed:8163524}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP = 3',5'-cyclic AMP + diphosphate; Xref=Rhea:RHEA:15389,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:33019, ChEBI:CHEBI:58165; EC=4.6.1.1;
CC         Evidence={ECO:0000269|PubMed:8163524, ECO:0000269|PubMed:8557635};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:8557635};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:8557635};
CC       Note=Binds 2 magnesium ions per subunit. Is also active with manganese
CC       (in vitro). {ECO:0000250|UniProtKB:P30803};
CC   -!- ACTIVITY REGULATION: At rest, the N- and C-terminal domains interact,
CC       as part of a larger autoinhibitory complex, with calmodulin pre-
CC       associated at the N-terminal domain. Upon a calcium rise, calmodulin
CC       becomes calcium-saturated and subsequently binds to the C-terminal
CC       domain. Fully calcium-saturated calmodulin then leaves the N-terminal
CC       domain, binding solely to the C-terminal domain, and the whole
CC       autoinhibitory complex dissociates, resulting in activation of
CC       adenylate cyclase. As local calcium concentrations decrease, the
CC       calmodulin becomes calcium free and binds once more to the N-terminal
CC       domain, whereupon the whole system returns to rest with the re-
CC       association of the autoinhibitory complex (PubMed:19305019,
CC       PubMed:8163524, PubMed:8557635). In non-excitable cells, activated by
CC       capacitative calcium entry (CCE) through store-operated channels,
CC       namely through interaction with ORAI1 and STIM1; membrane raft and
CC       caveolae localization and membrane integrity are indispensable
CC       (PubMed:11744699, PubMed:19158400, PubMed:19171672, PubMed:20410303,
CC       PubMed:22494970). CCE-mediated adenylate cyclase activity is decreased
CC       by AKAP5 and AKAP7. CCE-mediated adenylate cyclase activity is up-
CC       regulated by AKAP9 and the mitochondrially targeted AKAP1
CC       (PubMed:20410303). In excitable cells, activated during membrane
CC       depolarization through L-type voltage-gated calcium channels (VGCC),
CC       leading to calcium entry; the L-type alpha subunit is sufficient
CC       (PubMed:24086669, PubMed:25381556). Activated via stimulation of the
CC       GLP1R (PubMed:25381556). Synergistically activated by
CC       calcium/calmodulin and GNAS (PubMed:13680124). Stimulated by forskolin
CC       (PubMed:13680124, PubMed:16186630). Inhibited by PKA directly bound to
CC       AKAP5 at membrane raft (PubMed:21771783, PubMed:22976297). Inhibition
CC       by acute activation of OPRM1 and activation by chronic activation of
CC       OPRM1 is mediated by pertussis toxin-sensitive G(i) and G(o) G alpha
CC       proteins and G beta-gamma dimer. Activity is inhibited by G beta-gamma
CC       dimer (PubMed:16186630). {ECO:0000269|PubMed:11744699,
CC       ECO:0000269|PubMed:13680124, ECO:0000269|PubMed:16186630,
CC       ECO:0000269|PubMed:19158400, ECO:0000269|PubMed:19171672,
CC       ECO:0000269|PubMed:19305019, ECO:0000269|PubMed:20410303,
CC       ECO:0000269|PubMed:21771783, ECO:0000269|PubMed:22494970,
CC       ECO:0000269|PubMed:22976297, ECO:0000269|PubMed:24086669,
CC       ECO:0000269|PubMed:25381556, ECO:0000269|PubMed:8163524,
CC       ECO:0000269|PubMed:8557635}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.18 mM for ATP (in the presence of 5.74 mM free Mg(2+) and 1 muM
CC         exogenous calmodulin) (isoform 1) {ECO:0000269|PubMed:8557635};
CC         KM=0.16 mM for ATP (in the presence of 5.74 mM free Mg(2+) and 1 muM
CC         exogenous calmodulin) (isoform 2) {ECO:0000269|PubMed:8557635};
CC         KM=2.10 mM for ATP (in the presence of 5.74 mM free Mg(2+) and 1 muM
CC         exogenous calmodulin) (isoform 3) {ECO:0000269|PubMed:8557635};
CC         KM=0.038 mM for ATP (in the presence of 0.23 mM free Mn(2+) and 1 muM
CC         exogenous calmodulin) (isoform 1) {ECO:0000269|PubMed:8557635};
CC         KM=0.025 mM for ATP (in the presence of 0.23 mM free Mn(2+) and 1 muM
CC         exogenous calmodulin) (isoform 2) {ECO:0000269|PubMed:8557635};
CC         KM=0.116 mM for ATP (in the presence of 0.23 mM free Mn(2+) and 1 muM
CC         exogenous calmodulin) (isoform 3) {ECO:0000269|PubMed:8557635};
CC         Vmax=7.4 nmol/min/mg enzyme (in the presence of 5.74 mM free Mg(2+)
CC         and 1 muM exogenous calmodulin) (isoform 1)
CC         {ECO:0000269|PubMed:8557635};
CC         Vmax=2 nmol/min/mg enzyme (in the presence of 5.74 mM free Mg(2+) and
CC         1 muM exogenous calmodulin) (isoform 2) {ECO:0000269|PubMed:8557635};
CC         Vmax=1.5 nmol/min/mg enzyme (in the presence of 5.74 mM free Mg(2+)
CC         and 1 muM exogenous calmodulin) (isoform 3)
CC         {ECO:0000269|PubMed:8557635};
CC         Vmax=10.4 nmol/min/mg enzyme (in the presence of 0.23 mM free Mn(2+)
CC         and 1 muM exogenous calmodulin) (isoform 1)
CC         {ECO:0000269|PubMed:8557635};
CC         Vmax=3.5 nmol/min/mg enzyme (in the presence of 0.23 mM free Mn(2+)
CC         and 1 muM exogenous calmodulin) (isoform 2)
CC         {ECO:0000269|PubMed:8557635};
CC         Vmax=1.5 nmol/min/mg enzyme (in the presence of 0.23 mM free Mn(2+)
CC         and 1 muM exogenous calmodulin) (isoform 3)
CC         {ECO:0000269|PubMed:8557635};
CC   -!- SUBUNIT: Homodimer; via transmembrane domain (PubMed:11856299,
CC       PubMed:19158400). Monomer (PubMed:19158400). Heterodimer
CC       (PubMed:11856299). Oligemer; via transmembrane domain
CC       (PubMed:11856299). Interacts with PRKAR2A and AKAP5; inhibits adenylate
CC       cyclase activity through PKA phosphorylation (PubMed:22976297).
CC       Interacts with PPP2CA and PPP2R1A; does not mediate the inhibitory
CC       effects of PKA on adenylate cyclase activity; interaction is dependent
CC       of catalytically active PPP2CA; antagonizes interaction with calmodulin
CC       (PubMed:16258073, PubMed:22976297). Interacts with AKAP5 (palmitoylated
CC       form); promotes the phosphorylation of ADCY8 after store-operated
CC       calcium entry (SOCE) stimulation at membrane raft (PubMed:20410303,
CC       PubMed:21771783). Interacts with ORAI1; interaction is calcium store
CC       depletion independent; interaction occurs in membrane raft; interaction
CC       increases markedly after store depletion; positively regulates SOCE-
CC       induced adenylate cyclase activity; contributes to the targeting of
CC       ADCY8 to discrete regions of the plasma membrane that are shielded from
CC       other calcium events (PubMed:22494970). Interacts with STIM1
CC       (PubMed:22494970). Interacts with actin; interaction is calcium
CC       independent; interaction is affected by calcium-calmodulin; interaction
CC       controls the distribution and regulation of ADCY8 (PubMed:22399809).
CC       Interacts with calmodulin; at rest, interacts via N-terminal domain;
CC       upon a calcium rise, calmodulin becomes calcium-saturated and
CC       subsequently binds to the C-terminal domain forming an autoinhibitory
CC       complex; fully calcium-saturated calmodulin leaves the N-terminal
CC       domain, binding solely to the C-terminal domain leading to dissociation
CC       of autoinhibitory complex and resulting in activation of adenylate
CC       cyclase; antagonizes interaction with PPP2CA; interaction is calcium
CC       dependent (PubMed:16258073, PubMed:19305019, PubMed:22399809).
CC       Interacts with PPP2R5D (PubMed:22976297). {ECO:0000269|PubMed:11856299,
CC       ECO:0000269|PubMed:16258073, ECO:0000269|PubMed:19158400,
CC       ECO:0000269|PubMed:19305019, ECO:0000269|PubMed:20410303,
CC       ECO:0000269|PubMed:21771783, ECO:0000269|PubMed:22399809,
CC       ECO:0000269|PubMed:22494970, ECO:0000269|PubMed:22976297}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19171672,
CC       ECO:0000269|PubMed:21046358, ECO:0000269|PubMed:8163524}; Multi-pass
CC       membrane protein. Cell projection, dendrite
CC       {ECO:0000269|PubMed:16258073}. Membrane raft
CC       {ECO:0000269|PubMed:16258073, ECO:0000269|PubMed:19158400,
CC       ECO:0000269|PubMed:19171672, ECO:0000269|PubMed:22494970}. Membrane,
CC       coated pit {ECO:0000269|PubMed:19158400}. Cytoplasmic vesicle,
CC       clathrin-coated vesicle membrane {ECO:0000269|PubMed:19158400}.
CC       Membrane, caveola {ECO:0000269|PubMed:11744699}. Basolateral cell
CC       membrane {ECO:0000250|UniProtKB:P97490}. Apical cell membrane
CC       {ECO:0000250|UniProtKB:P97490}. Synapse {ECO:0000250|UniProtKB:P97490}.
CC       Cell projection, dendrite {ECO:0000250|UniProtKB:P97490}. Cell
CC       projection, axon {ECO:0000250|UniProtKB:P97490}. Presynaptic cell
CC       membrane {ECO:0000250|UniProtKB:P97490}. Postsynaptic density
CC       {ECO:0000250|UniProtKB:P97490}. Note=Localized to dendritic arbors (By
CC       similarity). Monomeric N-glycosylated specieslocalized in membrane
CC       raft. In contrast, monomeric unglycosylated forms are enriched in
CC       clathrin-coated pits and vesicles. Dimers are also localized outside of
CC       membrane rafts. Membrane raft localization and integrity is
CC       indispensable for CCE-stimulated adenylate cyclase activity
CC       (PubMed:19158400). {ECO:0000250|UniProtKB:P97490,
CC       ECO:0000269|PubMed:19158400}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=VIII-A {ECO:0000303|PubMed:8557635};
CC         IsoId=P40146-1; Sequence=Displayed;
CC       Name=2; Synonyms=VIII-B {ECO:0000303|PubMed:8557635};
CC         IsoId=P40146-2; Sequence=VSP_059987;
CC       Name=3; Synonyms=VIII-c {ECO:0000303|PubMed:8557635};
CC         IsoId=P40146-3; Sequence=VSP_059986;
CC       Name=4; Synonyms=VIII-D {ECO:0000303|PubMed:13680124};
CC         IsoId=P40146-4; Sequence=VSP_059986, VSP_059987;
CC   -!- TISSUE SPECIFICITY: Brain (PubMed:13680124, PubMed:8557635). Expressed
CC       in insulin-producing cells (PubMed:13680124).
CC       {ECO:0000269|PubMed:13680124, ECO:0000269|PubMed:8557635}.
CC   -!- INDUCTION: Reduces by glucose (PubMed:21046358). Up-regulated during
CC       vascular smooth muscle cell de-differentiation by IL1B
CC       (PubMed:16741924). {ECO:0000269|PubMed:16741924,
CC       ECO:0000269|PubMed:21046358}.
CC   -!- DOMAIN: The protein contains two modules with six transmembrane helices
CC       each; both are required for catalytic activity. Isolated N-terminal or
CC       C-terminal guanylate cyclase domains have no catalytic activity, but
CC       when they are brought together, enzyme activity is restored. The active
CC       site is at the interface of the two domains. Both contribute substrate-
CC       binding residues, but the catalytic metal ions are bound exclusively
CC       via the N-terminal guanylate cyclase domain. The two transmembrane
CC       clusters are necessary and suficient for the plasma membrane targeting
CC       and oligomers assembly (PubMed:11856299). The N-terminal and C-terminal
CC       domains interact at rest as part of a larger autoinhibitory complex,
CC       with calmodulin pre-associated at the N-terminal domain; the binding is
CC       specifically inhibited by fully calcium-saturated calmodulin, resulting
CC       in activation of AC8 (PubMed:19305019). {ECO:0000250|UniProtKB:P26769,
CC       ECO:0000269|PubMed:11856299, ECO:0000269|PubMed:19305019}.
CC   -!- PTM: Phosphorylated by PKA; mediates inhibition of adenylate cyclase
CC       activity at membrane raft; does not influence either CALM1 or PPP2CA
CC       interaction with ADCY8. {ECO:0000269|PubMed:21771783,
CC       ECO:0000269|PubMed:22976297}.
CC   -!- PTM: [Isoform 1]: N-glycosylated; N-glycosylation is responsible for
CC       raft-targeting; is not necessary for CCE-stimulated adenylate cyclase
CC       activity. {ECO:0000269|PubMed:19158400, ECO:0000269|PubMed:8557635}.
CC   -!- PTM: [Isoform 3]: N-glycosylated; N-glycosylation is responsible for
CC       raft-targeting; is not necessary for CCE-stimulated adenylate cyclase
CC       activity. {ECO:0000269|PubMed:19158400, ECO:0000269|PubMed:8557635}.
CC   -!- MISCELLANEOUS: [Isoform 3]: EC50 is approximately 4 times more
CC       sensitive to stimulation by calcium/calmodulin than isoform 1 and 2.
CC       {ECO:0000269|PubMed:8557635}.
CC   -!- SIMILARITY: Belongs to the adenylyl cyclase class-4/guanylyl cyclase
CC       family. {ECO:0000255|PROSITE-ProRule:PRU00099}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L26986; AAA20504.1; -; mRNA.
DR   PIR; A53588; A53588.
DR   RefSeq; NP_058838.1; NM_017142.1. [P40146-1]
DR   AlphaFoldDB; P40146; -.
DR   SMR; P40146; -.
DR   STRING; 10116.ENSRNOP00000006789; -.
DR   BindingDB; P40146; -.
DR   ChEMBL; CHEMBL2095179; -.
DR   DrugCentral; P40146; -.
DR   GlyCosmos; P40146; 3 sites, No reported glycans.
DR   GlyGen; P40146; 3 sites.
DR   iPTMnet; P40146; -.
DR   PhosphoSitePlus; P40146; -.
DR   PaxDb; 10116-ENSRNOP00000006789; -.
DR   GeneID; 29241; -.
DR   KEGG; rno:29241; -.
DR   UCSC; RGD:2036; rat. [P40146-1]
DR   AGR; RGD:2036; -.
DR   CTD; 114; -.
DR   RGD; 2036; Adcy8.
DR   eggNOG; KOG3619; Eukaryota.
DR   InParanoid; P40146; -.
DR   OrthoDB; 3686360at2759; -.
DR   PhylomeDB; P40146; -.
DR   BRENDA; 4.6.1.1; 5301.
DR   Reactome; R-RNO-163615; PKA activation.
DR   Reactome; R-RNO-170660; Adenylate cyclase activating pathway.
DR   Reactome; R-RNO-170670; Adenylate cyclase inhibitory pathway.
DR   Reactome; R-RNO-418597; G alpha (z) signalling events.
DR   Reactome; R-RNO-5610787; Hedgehog 'off' state.
DR   PRO; PR:P40146; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0016324; C:apical plasma membrane; ISS:UniProtKB.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0016323; C:basolateral plasma membrane; ISS:UniProtKB.
DR   GO; GO:0005901; C:caveola; IDA:UniProtKB.
DR   GO; GO:0005905; C:clathrin-coated pit; IDA:UniProtKB.
DR   GO; GO:0030665; C:clathrin-coated vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0030425; C:dendrite; IDA:UniProtKB.
DR   GO; GO:0060076; C:excitatory synapse; ISS:UniProtKB.
DR   GO; GO:0098978; C:glutamatergic synapse; ISO:RGD.
DR   GO; GO:0098686; C:hippocampal mossy fiber to CA3 synapse; ISO:RGD.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0032809; C:neuronal cell body membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0044853; C:plasma membrane raft; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; ISS:UniProtKB.
DR   GO; GO:0048786; C:presynaptic active zone; ISS:UniProtKB.
DR   GO; GO:0042734; C:presynaptic membrane; ISO:RGD.
DR   GO; GO:0098685; C:Schaffer collateral - CA1 synapse; ISO:RGD.
DR   GO; GO:0003779; F:actin binding; IDA:UniProtKB.
DR   GO; GO:0004016; F:adenylate cyclase activity; ISO:RGD.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008294; F:calcium- and calmodulin-responsive adenylate cyclase activity; IDA:UniProtKB.
DR   GO; GO:0005516; F:calmodulin binding; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0019902; F:phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0046983; F:protein dimerization activity; IDA:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IMP:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0051721; F:protein phosphatase 2A binding; IDA:UniProtKB.
DR   GO; GO:0034199; P:activation of protein kinase A activity; IMP:UniProtKB.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IMP:WormBase.
DR   GO; GO:0006171; P:cAMP biosynthetic process; IMP:RGD.
DR   GO; GO:0019933; P:cAMP-mediated signaling; IDA:RGD.
DR   GO; GO:0071277; P:cellular response to calcium ion; IDA:UniProtKB.
DR   GO; GO:1904322; P:cellular response to forskolin; IDA:UniProtKB.
DR   GO; GO:0071377; P:cellular response to glucagon stimulus; IMP:UniProtKB.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IDA:UniProtKB.
DR   GO; GO:0071315; P:cellular response to morphine; IDA:UniProtKB.
DR   GO; GO:0038003; P:G protein-coupled opioid receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0010255; P:glucose mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007626; P:locomotory behavior; ISS:UniProtKB.
DR   GO; GO:0007616; P:long-term memory; ISO:RGD.
DR   GO; GO:0007613; P:memory; ISS:UniProtKB.
DR   GO; GO:0050804; P:modulation of chemical synaptic transmission; ISO:RGD.
DR   GO; GO:0150076; P:neuroinflammatory response; ISS:UniProtKB.
DR   GO; GO:0032793; P:positive regulation of CREB transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IMP:UniProtKB.
DR   GO; GO:0032024; P:positive regulation of insulin secretion; ISO:RGD.
DR   GO; GO:0035774; P:positive regulation of insulin secretion involved in cellular response to glucose stimulus; IMP:UniProtKB.
DR   GO; GO:1900454; P:positive regulation of long-term synaptic depression; ISS:UniProtKB.
DR   GO; GO:1900273; P:positive regulation of long-term synaptic potentiation; ISS:UniProtKB.
DR   GO; GO:0031915; P:positive regulation of synaptic plasticity; ISS:UniProtKB.
DR   GO; GO:0051259; P:protein complex oligomerization; IDA:UniProtKB.
DR   GO; GO:0051260; P:protein homooligomerization; IMP:UniProtKB.
DR   GO; GO:0080135; P:regulation of cellular response to stress; ISS:UniProtKB.
DR   GO; GO:0051480; P:regulation of cytosolic calcium ion concentration; ISS:UniProtKB.
DR   CDD; cd07302; CHD; 2.
DR   Gene3D; 3.30.70.1230; Nucleotide cyclase; 2.
DR   InterPro; IPR001054; A/G_cyclase.
DR   InterPro; IPR018297; A/G_cyclase_CS.
DR   InterPro; IPR032628; AC_N.
DR   InterPro; IPR030672; Adcy.
DR   InterPro; IPR009398; Adcy_conserved_dom.
DR   InterPro; IPR029787; Nucleotide_cyclase.
DR   PANTHER; PTHR45627; ADENYLATE CYCLASE TYPE 1; 1.
DR   PANTHER; PTHR45627:SF1; ADENYLATE CYCLASE TYPE 8; 1.
DR   Pfam; PF16214; AC_N; 1.
DR   Pfam; PF06327; Adcy_cons_dom; 1.
DR   Pfam; PF00211; Guanylate_cyc; 2.
DR   PIRSF; PIRSF039050; Ade_cyc; 1.
DR   SMART; SM00044; CYCc; 2.
DR   SUPFAM; SSF55073; Nucleotide cyclase; 2.
DR   PROSITE; PS00452; GUANYLATE_CYCLASE_1; 2.
DR   PROSITE; PS50125; GUANYLATE_CYCLASE_2; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; cAMP biosynthesis; Cell membrane;
KW   Cell projection; Coated pit; Cytoplasmic vesicle; Glycoprotein; Lyase;
KW   Magnesium; Manganese; Membrane; Metal-binding; Methylation;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome; Repeat; Synapse;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..1248
FT                   /note="Adenylate cyclase type 8"
FT                   /id="PRO_0000195707"
FT   TOPO_DOM        1..179
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        180..200
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        209..229
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        244..264
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        271..291
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        293..313
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        318..338
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        339..712
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        713..733
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        735..755
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        784..804
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        828..848
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        858..878
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        891..911
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        912..1248
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          1..179
FT                   /note="Involved in ORAI1, STIM1, PPP2CA and PPP2R1A
FT                   interaction"
FT                   /evidence="ECO:0000269|PubMed:16258073,
FT                   ECO:0000269|PubMed:22494970, ECO:0000269|PubMed:22976297"
FT   REGION          1..106
FT                   /note="Involved in AKAP5 and PRKAR2A interaction"
FT                   /evidence="ECO:0000269|PubMed:22976297"
FT   REGION          51..117
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1106..1248
FT                   /note="Involved in CALM1 interaction"
FT                   /evidence="ECO:0000269|PubMed:16258073"
FT   REGION          1197..1212
FT                   /note="Required for both calcium stimulation and
FT                   maintenance of autoinhibition"
FT                   /evidence="ECO:0000269|PubMed:19305019"
FT   REGION          1220..1248
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           38..40
FT                   /note="Essential for CALM1 interaction"
FT                   /evidence="ECO:0000269|PubMed:16258073"
FT   MOTIF           49..51
FT                   /note="Essential for CALM1 interaction"
FT                   /evidence="ECO:0000269|PubMed:16258073"
FT   COMPBIAS        67..88
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         416..421
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P30803"
FT   BINDING         416
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00099"
FT   BINDING         416
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00099"
FT   BINDING         417
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00099"
FT   BINDING         458..460
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P30803"
FT   BINDING         460
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00099"
FT   BINDING         460
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00099"
FT   BINDING         504
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P30803"
FT   BINDING         1031
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P26769"
FT   BINDING         1106..1108
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P26769"
FT   BINDING         1113..1117
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P26769"
FT   BINDING         1153
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P26769"
FT   SITE            1196
FT                   /note="Essential for autoinhibition maintenance by
FT                   promoting interaction of the N and C termini"
FT                   /evidence="ECO:0000269|PubMed:19305019"
FT   SITE            1197
FT                   /note="Essential for autoinhibition maintenance"
FT                   /evidence="ECO:0000269|PubMed:19305019"
FT   SITE            1200
FT                   /note="Essential for autoinhibition maintenance by
FT                   promoting interaction of the N and C termini"
FT                   /evidence="ECO:0000269|PubMed:19305019"
FT   SITE            1202
FT                   /note="Essential for CALM1 interaction"
FT                   /evidence="ECO:0000269|PubMed:19305019"
FT   SITE            1204
FT                   /note="Essential for CALM1 interaction"
FT                   /evidence="ECO:0000269|PubMed:19305019"
FT   MOD_RES         55
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P97490"
FT   MOD_RES         611
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P97490"
FT   MOD_RES         621
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   CARBOHYD        814
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        818
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        885
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         635..700
FT                   /note="Missing (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000269|PubMed:13680124,
FT                   ECO:0000269|PubMed:8557635"
FT                   /id="VSP_059986"
FT   VAR_SEQ         802..831
FT                   /note="Missing (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000269|PubMed:13680124,
FT                   ECO:0000269|PubMed:8557635"
FT                   /id="VSP_059987"
FT   MUTAGEN         1..106
FT                   /note="Missing: Does not affect adenylate cyclase activity
FT                   in response to calcium in vitro. Reduces adenylate cyclase
FT                   activity in response to capacitative calcium entry (CCE).
FT                   Reduces colocalization with actin. Does not improve the
FT                   distribution of the actin cytoskeleton at the plasma
FT                   membrane."
FT                   /evidence="ECO:0000269|PubMed:22399809"
FT   MUTAGEN         38..40
FT                   /note="WQT->AAA: Does not interact with CALM1; when
FT                   associated with 49-A--A-51. Interacts with PPP2CA; when
FT                   associated with 49-A--A-51. Greatly reduces CCE-stimulated
FT                   adenylate cyclase activity; when associated with 49-A--A-
FT                   51. Does not affect caveolar localization; when associated
FT                   with 49-A--A-51. Does not affect calcium/calmodulin
FT                   stimulated adenylate cyclase activity; when associated with
FT                   49-A--A-51. Decreases calcium/calmodulin stimulated
FT                   adenylate cyclase activity; when associated with 49-A--A-
FT                   51; A-1197; A-1198 and A-1202."
FT                   /evidence="ECO:0000269|PubMed:11744699,
FT                   ECO:0000269|PubMed:16258073, ECO:0000269|PubMed:19305019"
FT   MUTAGEN         49..51
FT                   /note="RFI->AAA: Does not interact with CALM1; when
FT                   associated with 38-A--A-40. Interacts with PPP2CA; when
FT                   associated with 38-A--A-40. Greatly reduces CCE-stimulated
FT                   adenylate cyclase activity; when associated with 38-A--A-
FT                   40. Does not affect caveolar localization; when associated
FT                   with 38-A--A-40.Does not affect calcium/calmodulin
FT                   stimulated adenylate cyclase activity; when associated with
FT                   38-A--A-40. Decreases calcium/calmodulin stimulated
FT                   adenylate cyclase activity; when associated with 38-A--A-
FT                   40; A-1197; A-1198 and A-1202."
FT                   /evidence="ECO:0000269|PubMed:11744699,
FT                   ECO:0000269|PubMed:16258073, ECO:0000269|PubMed:19305019"
FT   MUTAGEN         66
FT                   /note="S->A: Decraeses significantly the stimulatoty effect
FT                   of PKA inhibitor on calcium-stimulated adenylate cyclase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:22976297"
FT   MUTAGEN         112
FT                   /note="S->A: Loses the stimulatoty effect of PKA inhibitor
FT                   on calcium-stimulated adenylate cyclase activity."
FT                   /evidence="ECO:0000269|PubMed:22976297"
FT   MUTAGEN         112
FT                   /note="S->D: Insensitive to the stimulatory effect of PKA
FT                   inhibitor on calcium-stimulated adenylate cyclase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:22976297"
FT   MUTAGEN         178
FT                   /note="S->A: Does not affect the stimulatoty effect of PKA
FT                   inhibitor on calcium-stimulated adenylate cyclase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:22976297"
FT   MUTAGEN         416
FT                   /note="D->N: Loses adenylate cyclase activity in response
FT                   to calcium."
FT                   /evidence="ECO:0000269|PubMed:22399809"
FT   MUTAGEN         432
FT                   /note="L->A: Does not affect dimerization; when associated
FT                   with A-439. Dramatically reduces the levels of the N-
FT                   glycosylated monomeric species; when associated with A-439.
FT                   Loss of calcium- and calmodulin-responsive adenylate
FT                   cyclase activity; when associated with A-439. Affects
FT                   membrane raft localization; when associated with A-439."
FT                   /evidence="ECO:0000269|PubMed:19158400"
FT   MUTAGEN         439
FT                   /note="L->A: Does not affect dimerization. Does not affect
FT                   dimerization;when associated with A-432. Does not affect
FT                   dimerization;when associated with A-446 and A-432. Does not
FT                   affect dimerization;when associated with A-432; A-446 and
FT                   A-453. Dramatically reduces the levels of the N-
FT                   glycosylated monomeric species. Dramatically reduces the
FT                   levels of the N-glycosylated monomeric species; when
FT                   associated with A-432.Dramatically reduces the levels of
FT                   the N-glycosylated monomeric species; when associated with
FT                   A-446 and A-432. Dramatically reduces the levels of the N-
FT                   glycosylated monomeric species; when associated with A-453;
FT                   A-432 and A-446. Loss of calcium- and calmodulin-responsive
FT                   adenylate cyclase activity. Loss of calcium- and
FT                   calmodulin-responsive adenylate cyclase activity; when
FT                   associated with A-432. Loss of calcium- and calmodulin-
FT                   responsive adenylate cyclase activity; when associated with
FT                   A-446 and A-432. Loss of calcium- and calmodulin-responsive
FT                   adenylate cyclase activity; when associated with A-453; A-
FT                   432 and A-446. Affects membrane raft localization. Affects
FT                   membrane raft localization; when associated with A-432.
FT                   Affects membrane raft localization; when associated with A-
FT                   446 and A-432. Affects membrane raft localization; when
FT                   associated with A-439; A-432 and A-446."
FT                   /evidence="ECO:0000269|PubMed:19158400"
FT   MUTAGEN         446
FT                   /note="L->A: Does not affect dimerization; when associated
FT                   with A-439 and A-432. Dramatically reduces the levels of
FT                   the N-glycosylated monomeric species; when associated with
FT                   A-439 and A-432. Loss of calcium- and calmodulin-responsive
FT                   adenylate cyclase activity; when associated with A-439 and
FT                   A-432. Affects membrane raft localization; when associated
FT                   with A-439 and A-432."
FT                   /evidence="ECO:0000269|PubMed:19158400"
FT   MUTAGEN         453
FT                   /note="L->A: Does not affect dimerization; when associated
FT                   with A-439; A-432 and A-446. Dramatically reduces the
FT                   levels of the N-glycosylated monomeric species; when
FT                   associated with A-439; A-432 and A-446. Loss of
FT                   calcium- and calmodulin-responsive adenylate cyclase
FT                   activity; when associated with A-439; A-432 and A-446.
FT                   Affects membrane raft localization; when associated with A-
FT                   439; A-432 and A-446."
FT                   /evidence="ECO:0000269|PubMed:19158400"
FT   MUTAGEN         611
FT                   /note="S->A: Does not affect the stimulatoty effect of PKA
FT                   inhibitoron calcium-stimulated adenylate cyclase activity."
FT                   /evidence="ECO:0000269|PubMed:22976297"
FT   MUTAGEN         814
FT                   /note="N->Q: Does not affect deglycosylation. Does not
FT                   affect plasma membrane targeting; when associated with Q-
FT                   818 and A-885. Affects membrane raft localization; when
FT                   associated with Q-818 and A-885. Does not affect CCE-
FT                   stimulated adenylate cyclase activity; when associated with
FT                   Q-818 and A-885."
FT                   /evidence="ECO:0000269|PubMed:19158400"
FT   MUTAGEN         818
FT                   /note="N->Q: Does not affect deglycosylation. Does not
FT                   affect plasma membrane targeting; when associated with Q-
FT                   814 and A-885. Affects membrane raft localization; when
FT                   associated with Q-814 and A-885. Does not affect CCE-
FT                   stimulated adenylate cyclase activity; when associated with
FT                   Q-814 and A-885."
FT                   /evidence="ECO:0000269|PubMed:19158400"
FT   MUTAGEN         852
FT                   /note="S->A: Does not affect the stimulatoty effect of PKA
FT                   inhibitoron calcium-stimulated adenylate cyclase activity."
FT                   /evidence="ECO:0000269|PubMed:22976297"
FT   MUTAGEN         885
FT                   /note="N->E: Does not affect deglycosylation. Does not
FT                   affect plasma membrane targeting; when associated with Q-
FT                   814 and A-818. Affects membrane raft localization; when
FT                   associated with Q-814 and A-818. Does not affect CCE-
FT                   stimulated adenylate cyclase activity; when associated with
FT                   Q-814 and A-818."
FT                   /evidence="ECO:0000269|PubMed:19158400"
FT   MUTAGEN         1120
FT                   /note="S->A: Does not affect the stimulatoty effect of PKA
FT                   inhibitor on calcium-stimulated adenylate cyclase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:22976297"
FT   MUTAGEN         1196
FT                   /note="L->A: Consistently high basal adenylate cyclase
FT                   activity; when associated with A-1200. Does not affect
FT                   calmodulin binding; when associated with A-1200."
FT                   /evidence="ECO:0000269|PubMed:19305019"
FT   MUTAGEN         1197
FT                   /note="V->A: Does not affect calcium activated adenylate
FT                   cyclase; when associated with A-1198. Does not affect
FT                   calcium activated adenylate cyclase; when associated with
FT                   A-1198 and A-1202.Decreases calcium/calmodulin stimulated
FT                   adenylate cyclase activity; when associated with 49-A--A-
FT                   51; 38-A--A-40; A-1198 and A-1202. Has an elevated basal
FT                   activity; when associated with A-1198. Has an elevated
FT                   basal activity; when associated with A-1198 and A-1202.
FT                   Does not affect calmodulin binding; when associated with A-
FT                   1198. Does not affect calmodulin binding; when associated
FT                   with A-1198 and A-1202."
FT                   /evidence="ECO:0000269|PubMed:19305019"
FT   MUTAGEN         1197
FT                   /note="V->N: Does not affect calcium activated adenylate
FT                   cyclase. Significant high basal adenylate cyclase activity.
FT                   Significant high basal adenylate cyclase activity; when
FT                   associated with Q-1202."
FT                   /evidence="ECO:0000269|PubMed:19305019"
FT   MUTAGEN         1198
FT                   /note="Q->A: Does not affect calcium activated adenylate
FT                   cyclase; when associated with A-1197. Does not affect
FT                   calcium activated adenylate cyclase; when associated with
FT                   A-1197 and A-1202. Decreases calcium/calmodulin stimulated
FT                   adenylate cyclase activity; when associated with 49-A--A-
FT                   51; 38-A--A-40; A-1197 and A-1202. Has an elevated basal
FT                   activity; when associated with A-1197. Has an elevated
FT                   basal activity; when associated with A-1197 and A-1202.
FT                   Does not affect calmodulin binding; when associated with A-
FT                   1197. Does not affect calmodulin binding; when associated
FT                   with A-1197 and A-1202."
FT                   /evidence="ECO:0000269|PubMed:19305019"
FT   MUTAGEN         1198
FT                   /note="Q->K: Does not affect calcium activated adenylate
FT                   cyclase."
FT                   /evidence="ECO:0000269|PubMed:19305019"
FT   MUTAGEN         1199
FT                   /note="S->D: Increased CCE-stimulated adenylate cyclase
FT                   activity. Has a high basal activity."
FT                   /evidence="ECO:0000269|PubMed:19305019"
FT   MUTAGEN         1200
FT                   /note="L->A: Consistently high basal adenylate cyclase
FT                   activity; when associated with A-1196. Does not affect
FT                   calmodulin binding; when associated with A-1196."
FT                   /evidence="ECO:0000269|PubMed:19305019"
FT   MUTAGEN         1202
FT                   /note="R->A: Does not affect calcium activated adenylate
FT                   cyclase; when associated with A-1197 and A-1198. Decreases
FT                   calcium/calmodulin stimulated adenylate cyclase activity;
FT                   when associated with 49-A--A-51; 38-A--A-40; A-1197 and A-
FT                   1198. Has an elevated basal activity; when associated with
FT                   A-1197 and A-1198. Does not affect calmodulin binding; when
FT                   associated with A-1197 and A-1198."
FT                   /evidence="ECO:0000269|PubMed:19305019"
FT   MUTAGEN         1202
FT                   /note="R->E: Does not affect calcium activated adenylate
FT                   cyclase; when associated with E-1204. Greatly diminishes
FT                   calmodulin binding; when associated with E-1204."
FT                   /evidence="ECO:0000269|PubMed:19305019"
FT   MUTAGEN         1202
FT                   /note="R->Q: Does not affect calcium activated adenylate
FT                   cyclase. Increases slightly basal adenylate cyclase
FT                   activity but not significantly, and retains an appreciable
FT                   calcium regulation. Significant high basal adenylate
FT                   cyclase activity; when associated with N-1197."
FT                   /evidence="ECO:0000269|PubMed:19305019"
FT   MUTAGEN         1204
FT                   /note="R->E: Does not affect calcium activated adenylate
FT                   cyclase; when associated with E-1202. Greatly diminishes
FT                   calmodulin binding; when associated with E-1202."
FT                   /evidence="ECO:0000269|PubMed:19305019"
FT   MUTAGEN         1206
FT                   /note="K->E: Does not affect calcium activated adenylate
FT                   cyclase. Does not affect calmodulin binding."
FT                   /evidence="ECO:0000269|PubMed:19305019"
FT   MUTAGEN         1208
FT                   /note="L->E: Does not affect calcium activated adenylate
FT                   cyclase; when associated with E-1209. Does not affect
FT                   calmodulin binding; when associated with E-1209."
FT                   /evidence="ECO:0000269|PubMed:19305019"
FT   MUTAGEN         1209
FT                   /note="L->E: Does not affect calcium activated adenylate
FT                   cyclase; when associated with E-1208. Does not affect
FT                   calmodulin binding; when associated with E-1208."
FT                   /evidence="ECO:0000269|PubMed:19305019"
SQ   SEQUENCE   1248 AA;  139823 MW;  0171A3CEED034961 CRC64;
     MELSDVHCLS GSEELYTIHP TPPAADGGSG SRPQRLLWQT AVRHITEQRF IHGHRGGGGG
     GSRKASNPAG SGPNHHAPQL SSDSVLPLYS LGSGERAHNT GGTKVFPERS GSGSASGSGG
     GGDLGFLHLD CAPSNSDFFL NGGYSYRGVI FPTLRNSFKS RDLERLYQRY FLGQRRKSEV
     VMNVLDVLTK LTLLVLHLSL ASAPMDPLKG ILLGFFTGIE VVICALVVVR KDTTSHTYLQ
     YSGVVTWVAM TTQILAAGLG YGLLGDGIGY VLFTLFATYS MLPLPLTWAI LAGLGTSLLQ
     VTLQVLIPRL AVFSINQVLA QVVLFMCMNT AGIFISYLSD RAQRQAFLET RRCVEARLRL
     ETENQRQERL VLSVLPRFVV LEMINDMTNV EDEHLQHQFH RIYIHRYENV SILFADVKGF
     TNLSTTLSAQ ELVRMLNELF ARFDRLAHEH HCLRIKILGD CYYCVSGLPE PRQDHAHCCV
     EMGLSMIKTI RFVRSRTKHD VDMRIGIHSG SVLCGVLGLR KWQFDVWSWD VDIANKLESG
     GIPGRIHISK ATLDCLSGDY NVEEGHGKER NEFLRKHNIE TYLIKQPEES LLSLPEDIVK
     ESVSCSDRRN SGATFTEGSW SPELPFDNIV GKQNTLAALT RNSINLLPNH LAQALHVQSG
     PEEINKRIEH TIDLRSGDKL RREHIKPFSL MFKDSSLEHK YSQMRDEVFK SNLVCAFIVL
     LFITAIQSLL PSSRLMPMTI QFSILIMLHS ALVLITTAED YKCLPLILRK TCCWINETYL
     ARNVIIFASI LINFLGAVIN ILWCDFDKSI PLKNLTFNSS AVFTDICSYP EYFVFTGVLA
     MVTCAVFLRL NSVLKLAVLL IMIAIYALLT ETIYAGLFLS YDNLNHSGED FLGTKEASLL
     LMAMFLLAVF YHGQQLEYTA RLDFLWRVQA KEEINEMKDL REHNENMLRN ILPGHVARHF
     LEKDRDNEEL YSQSYDAVGV MFASIPGFAD FYSQTEMNNQ GVECLRLLNE IIADFDELLG
     EDRFQDIEKI KTIGSTYMAV SGLSPEKQQC EDKWGHLCAL ADFSLALTES IQEINKHSFN
     NFELRIGISH GSVVAGVIGA KKPQYDIWGK TVNLASRMDS TGVSGRIQVP EETYLILKDQ
     GFAFDYRGEI YVKGISEQEG KIKTYFLLGR VQPNPFILPP RRLPGQYSLA AVVLGLVQSL
     NRQRQKQLLN ENSNSGIIKS HYNRRTLLTP SGPEPGAQAE GTDKSDLP
//
